UA108986C2 - Кристалічна форма гідрохлориду ((1s,2s,4r)-4-{4-[(1s)-2,3-дигідро-1h-інден-1-іламіно]-7h-піроло[2,3-d]піримідин-7іл}-2-гідроксициклопентил)метилсульфамату (варіанти) - Google Patents

Кристалічна форма гідрохлориду ((1s,2s,4r)-4-{4-[(1s)-2,3-дигідро-1h-інден-1-іламіно]-7h-піроло[2,3-d]піримідин-7іл}-2-гідроксициклопентил)метилсульфамату (варіанти) Download PDF

Info

Publication number
UA108986C2
UA108986C2 UAA201114830A UAA201114830A UA108986C2 UA 108986 C2 UA108986 C2 UA 108986C2 UA A201114830 A UAA201114830 A UA A201114830A UA A201114830 A UAA201114830 A UA A201114830A UA 108986 C2 UA108986 C2 UA 108986C2
Authority
UA
Ukraine
Prior art keywords
cancer
compound
crystalline form
formula
prd
Prior art date
Application number
UAA201114830A
Other languages
English (en)
Russian (ru)
Ukrainian (uk)
Inventor
Іан Г. Армітейдж
Иан Г. Армитейдж
Реєну Чопра
Реену ЧОПРА
Мартін Іан Купер
Мартин Иан КУПЕР
Меріанн Ленгстон
Мерианн Ленгстон
Стефен П. Ленгстон
Степан Віскочіл
Степан Вискочил
Original Assignee
Мілленніум Фармасьютікалз, Інк.
Милленниум Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мілленніум Фармасьютікалз, Інк., Милленниум Фармасьютикалз, Инк. filed Critical Мілленніум Фармасьютікалз, Інк.
Publication of UA108986C2 publication Critical patent/UA108986C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
UAA201114830A 2009-05-14 2010-05-13 Кристалічна форма гідрохлориду ((1s,2s,4r)-4-{4-[(1s)-2,3-дигідро-1h-інден-1-іламіно]-7h-піроло[2,3-d]піримідин-7іл}-2-гідроксициклопентил)метилсульфамату (варіанти) UA108986C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21622109P 2009-05-14 2009-05-14
PCT/US2010/001415 WO2010132110A1 (en) 2009-05-14 2010-05-13 Hydrochloride salt of ((1s,2s,4r)-4-{4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo [2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate

Publications (1)

Publication Number Publication Date
UA108986C2 true UA108986C2 (uk) 2015-07-10

Family

ID=42396430

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201114830A UA108986C2 (uk) 2009-05-14 2010-05-13 Кристалічна форма гідрохлориду ((1s,2s,4r)-4-{4-[(1s)-2,3-дигідро-1h-інден-1-іламіно]-7h-піроло[2,3-d]піримідин-7іл}-2-гідроксициклопентил)метилсульфамату (варіанти)

Country Status (18)

Country Link
US (2) US9187482B2 (enExample)
EP (2) EP2430026A1 (enExample)
JP (3) JP2012526808A (enExample)
KR (2) KR20170102381A (enExample)
CN (2) CN102421780A (enExample)
AU (1) AU2010248151B2 (enExample)
BR (1) BRPI1012142A2 (enExample)
CA (1) CA2761256C (enExample)
IL (1) IL216201A (enExample)
MX (1) MX2011012108A (enExample)
NZ (2) NZ596470A (enExample)
PE (2) PE20120907A1 (enExample)
PH (1) PH12015501925A1 (enExample)
RU (1) RU2562245C2 (enExample)
SG (2) SG10201402148SA (enExample)
UA (1) UA108986C2 (enExample)
WO (1) WO2010132110A1 (enExample)
ZA (1) ZA201108347B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8008307B2 (en) 2006-08-08 2011-08-30 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as inhibitors of E1 activating enzymes
CA2949336C (en) 2007-08-02 2018-11-06 Lei Zhu Process for the synthesis of e1 activating enzyme inhibitors
CN102421780A (zh) 2009-05-14 2012-04-18 米伦纽姆医药公司 氨基磺酸((1s，2s，4r)-4-{4-[(1s)-2，3-二氢-1h-茚-1-基氨基]-7h-吡咯并[2，3-d]嘧啶-7-基}-2-羟基环戊基)甲酯盐酸盐
US20120115892A1 (en) * 2010-11-05 2012-05-10 Millennium Pharmaceuticals, Inc. Administration of nedd8-activating enzyme inhibitor
MY166889A (en) * 2011-08-24 2018-07-24 Millennium Pharm Inc Inhibitors of nedd8-activating enzyme
KR101987861B1 (ko) 2011-11-03 2019-06-11 밀레니엄 파머슈티컬스 인코퍼레이티드 Nedd-8 활성화 효소 억제제 및 저메틸화제의 투여
UA116534C2 (uk) 2012-02-17 2018-04-10 Мілленніум Фармасьютікалз, Інк. Піразолопіримідинілові інгібітори убіквітинактивуючого ферменту
US9593121B2 (en) 2012-08-03 2017-03-14 Millennium Pharmaceuticals, Inc. Indole substituted pyrrolopyrimidinyl inhibitors of Uba6
WO2014055543A2 (en) 2012-10-01 2014-04-10 Millennium Pharmaceuticals, Inc. Biomarkers and methods to predict response to inhibitors and uses thereof
EP2996773B1 (en) 2013-05-14 2020-09-16 Millennium Pharmaceuticals, Inc. Administration of nedd8-activating enzyme inhibitor and chemotherapeutic agents
EA032577B1 (ru) 2013-07-02 2019-06-28 Милленниум Фармасьютикалз, Инк. Гетероарильные соединения, пригодные в качестве ингибиторов sumo-активирующего фермента
RS59474B1 (sr) 2014-07-01 2019-12-31 Millennium Pharm Inc Heteroarilna jedinjenja koja su korisna kao inhibitori sumo-aktivirajućeg enzima
CN106008394B (zh) * 2016-05-23 2018-12-04 中国人民解放军第二军医大学 巯基苯并噻唑酰胺类化合物及其制备与作为药物的用途
JP2020534331A (ja) * 2017-09-21 2020-11-26 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． （（１ｓ，２ｓ，４ｒ）−４−｛４−［（１ｓ）−２，３−ジヒドロ−１ｈ−インデン−１−イルアミノ］−７ｈ−ピロロ［２，３−ｄ］ピリミジン−７−イル｝−２−ヒドロキシシクロペンチル）メチルスルファメートの共結晶形態、その製剤及び使用
JP2022521972A (ja) * 2019-02-26 2022-04-13 ミレニアム ファーマシューティカルズ， インコーポレイテッド アジュバントとして有用な化合物
KR20210115680A (ko) 2020-03-16 2021-09-27 서희강 연설용 프롬프터
WO2022112951A1 (en) 2020-11-25 2022-06-02 Takeda Pharmaceutical Company Limited Solid state forms of hydrochloride salt of ((1s,2s,4r)-4-{4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo[2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3622561A (en) 1969-08-18 1971-11-23 Univ Utah Nucleoside sugar esters of sulfamic acid and method for preparation of the same
US4252951A (en) * 1979-10-09 1981-02-24 Eli Lilly And Company Isolation of syn-7-(2-amino-4-thiazolyl)-(methoxyimino)acetamido-3-acetoxymethyl-3-cephem-4-carboxylic acid
JPS62108897A (ja) 1985-11-05 1987-05-20 Rikagaku Kenkyusho アスカマイシン誘導体及びその合成法並びに制癌剤
GB8813148D0 (en) 1988-06-03 1988-07-06 Glaxo Group Ltd Chemical compounds
GB8826205D0 (en) 1988-11-09 1988-12-14 Wellcome Found Heterocyclic compounds
US5726302A (en) 1989-09-15 1998-03-10 Gensia Inc. Water soluble adenosine kinase inhibitors
US5864033A (en) 1989-09-15 1999-01-26 Metabasis Therapeutics, Inc. Adenosine kinase inhibitors
US5763596A (en) 1989-09-15 1998-06-09 Metabasis Therapeutics, Inc. C-4' modified adenosine kinase inhibitors
US5721356A (en) 1989-09-15 1998-02-24 Gensia, Inc. Orally active adenosine kinase inhibitors
US5674998A (en) 1989-09-15 1997-10-07 Gensia Inc. C-4' modified adenosine kinase inhibitors
US5470898A (en) 1993-06-30 1995-11-28 Montell North America Inc. Sorbitol derivatives as nucleators and clarifiers for polyolefins, and polyolefin compositions obtained therewith
GB9325809D0 (en) 1993-12-17 1994-02-23 Zeneca Ltd Herbicidal composition
GB9325810D0 (en) 1993-12-17 1994-02-23 Zeneca Ltd Herbicidal composition
US6210917B1 (en) 1993-12-29 2001-04-03 The Regents Of The University Of California Method for suppressing multiple drug resistance in cancer cells
US5767097A (en) 1996-01-23 1998-06-16 Icn Pharmaceuticals, Inc. Specific modulation of Th1/Th2 cytokine expression by ribavirin in activated T-lymphocytes
US5973161A (en) 1996-03-18 1999-10-26 The University Of North Carolina At Chapel Hill Enantioselective synthesis of cyclopentenes
US5824657A (en) 1997-03-18 1998-10-20 Cubist Pharmaceuticals, Inc. Aminoacyl sulfamides for the treatment of hyperproliferative disorders
US6734283B1 (en) 1997-12-19 2004-05-11 Millennium Pharmaceuticals, Inc. Human proteins responsible for NEDD8 activation and conjugation
JPH11228422A (ja) 1998-02-16 1999-08-24 Mitsubishi Chemical Corp 抗マラリア剤
JPH11228446A (ja) 1998-02-16 1999-08-24 Mitsubishi Chemical Corp 抗マラリア剤
EP1411954B1 (en) 2000-10-18 2010-12-15 Pharmasset, Inc. Modified nucleosides for treatment of viral infections and abnormal cellular proliferation
EP1474147B1 (en) 2001-12-07 2010-05-05 Vertex Pharmaceuticals Incorporated Pyrimidine-based compounds useful as gsk-3 inhibitors
WO2003106477A1 (en) 2002-06-01 2003-12-24 Isis Pharmaceuticals, Inc. Oligomeric compounds that include carbocyclic nucleosides and their use in gene modulation
WO2005007621A2 (en) 2003-05-30 2005-01-27 Rigel Pharmaceuticals, Inc. Ubiquitin ligase inhibitors
US7338957B2 (en) 2003-08-28 2008-03-04 Irm Llc Compounds and compositions as protein kinase inhibitors
US20050130974A1 (en) 2003-10-17 2005-06-16 Rigel Pharmaceuticals, Inc. Benzothiazole compositions and their use as ubiquitin ligase inhibitors
US20090036448A1 (en) 2004-03-30 2009-02-05 Taisho Pharmecutical Co., Ltd. Pyrimidine derivatives and methods of treatment related to the use thereof
WO2006002284A1 (en) 2004-06-22 2006-01-05 Rigel Pharmaceuticals, Inc. Ubiquitin ligase inhibitors
EP1848718B1 (en) 2005-02-04 2012-08-01 Millennium Pharmaceuticals, Inc. Inhibitors of e1 activating enzymes
CN106008512B (zh) * 2006-02-02 2019-03-12 千禧药品公司 E1活化酶抑制剂
NZ574513A (en) * 2006-08-08 2012-02-24 Millennium Pharm Inc Heteroaryl compounds useful as inhibitors of e1 activating enzymes
CA2949336C (en) * 2007-08-02 2018-11-06 Lei Zhu Process for the synthesis of e1 activating enzyme inhibitors
CN102421780A (zh) 2009-05-14 2012-04-18 米伦纽姆医药公司 氨基磺酸((1s，2s，4r)-4-{4-[(1s)-2，3-二氢-1h-茚-1-基氨基]-7h-吡咯并[2，3-d]嘧啶-7-基}-2-羟基环戊基)甲酯盐酸盐
KR101987861B1 (ko) 2011-11-03 2019-06-11 밀레니엄 파머슈티컬스 인코퍼레이티드 Nedd-8 활성화 효소 억제제 및 저메틸화제의 투여
EP2996773B1 (en) 2013-05-14 2020-09-16 Millennium Pharmaceuticals, Inc. Administration of nedd8-activating enzyme inhibitor and chemotherapeutic agents

Also Published As

Publication number Publication date
JP2017105816A (ja) 2017-06-15
EP3091020B1 (en) 2020-12-30
RU2011150826A (ru) 2013-06-20
AU2010248151B2 (en) 2016-07-14
US20170000792A9 (en) 2017-01-05
PE20161222A1 (es) 2016-12-01
ZA201108347B (en) 2014-05-26
RU2562245C2 (ru) 2015-09-10
KR20170102381A (ko) 2017-09-08
US20160030432A1 (en) 2016-02-04
EP3091020A2 (en) 2016-11-09
KR20120024715A (ko) 2012-03-14
PE20120907A1 (es) 2012-08-18
JP2015096547A (ja) 2015-05-21
NZ621128A (en) 2015-08-28
IL216201A (en) 2015-11-30
SG175929A1 (en) 2011-12-29
AU2010248151A1 (en) 2011-12-01
PH12015501925A1 (en) 2018-01-22
BRPI1012142A2 (pt) 2016-03-29
MX2011012108A (es) 2011-12-08
US20110021544A1 (en) 2011-01-27
CN102421780A (zh) 2012-04-18
JP2012526808A (ja) 2012-11-01
US9187482B2 (en) 2015-11-17
US10016427B2 (en) 2018-07-10
EP2430026A1 (en) 2012-03-21
EP3091020A3 (en) 2017-01-11
IL216201A0 (en) 2012-01-31
NZ596470A (en) 2014-04-30
CA2761256A1 (en) 2010-11-18
WO2010132110A1 (en) 2010-11-18
CN104016987A (zh) 2014-09-03
SG10201402148SA (en) 2014-07-30
CA2761256C (en) 2021-01-05

Similar Documents

Publication Publication Date Title
UA108986C2 (uk) Кристалічна форма гідрохлориду ((1s,2s,4r)-4-{4-[(1s)-2,3-дигідро-1h-інден-1-іламіно]-7h-піроло[2,3-d]піримідин-7іл}-2-гідроксициклопентил)метилсульфамату (варіанти)
CA2532049C (en) Isethionate salt of a selective cdk4 inhibitor
ES2975263T3 (es) Formas cristalinas de un compuesto triazolopirimidínico
CA3099037A1 (en) Rip1 inhibitory compounds and methods for making and using the same
CN110650963B (zh) Gdc-0077的多晶型物和固体形式及其制备方法
WO2021113661A1 (en) Amorphous and polymorphic form of a specific chk1 inhibitor
US11124519B2 (en) Cocrystal forms of ((1S,2S,4R)-4-{4-[(1S)-2,3-dihydro-1H-inden-1-ylamino]-7H-pyrrolo [2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl) methyl sulfamate, formulations and uses thereof
US20240368165A1 (en) Solid state forms of hydrochloride salt of ((1s,2s,4r)-4-{4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo[2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate
CA2863085C (en) Mglu 2/3 agonists
HK1231052A1 (en) Hydrochloride salt of ((1s,2s,4r)-4-{4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo[2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate
AU2013204831A1 (en) Hydrochloride salt of ((1S,2S,4R)-4-{4-[(1S)-2,3-dihydro-1H-inden-1-ylamino] -7H-pyrrolo [2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate
BR122024009277A2 (pt) Formas cristalinas de um composto de triazolopirimidina
BR112018076443B1 (pt) Processo de preparação de formas cristalinas de um composto de triazolopirimidina